Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Imfinzi (durvalumab)
Pharma
AZ's $80B revenue target 'very much within reach,' CFO says
AZ's oncology chief suggested the PD-L1 inhibitor Imfinzi will likely be the company's largest oncology medicine by sales “in the midterm period.”
Angus Liu
Jan 14, 2026 10:00am
AZ's Imfinzi bags perioperative OK in early-stage stomach cancer
Nov 25, 2025 4:55pm
AZ CEO: 'We can absorb the impact' of US drug pricing deal
Nov 6, 2025 10:40am
AZ faces FDA challenge as Imfinzi-Lynparza miss survival goal
Oct 19, 2025 4:15am
Keytruda, Padcev cut risk of death by 50% in MIBC patient subset
Oct 18, 2025 10:30am
AZ's Imfinzi looks set up for another bladder cancer expansion
Oct 17, 2025 8:10am
